Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib

被引：21

作者：

Dengler, J ^{[1
]}

von Bubnoff, N ^{[1
]}

Decker, T ^{[1
]}

Peschel, C ^{[1
]}

Duyster, J ^{[1
]}

机构：

[1] Tech Univ Munich, Dept Internal Med 3, D-81675 Munich, Germany

来源：

LEUKEMIA | 2005年 / 19卷 / 10期

关键词：

D O I：

10.1038/sj.leu.2403848

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1835 / 1838

页数：4

共 8 条

[1] QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].

CHOU, TC ;

TALALAY, P .

ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55

[2] The molecular biology of chronic myeloid leukemia [J].

Deininger, MWN ;

Goldman, JM ;

Melo, JV .

BLOOD, 2000, 96 (10) :3343-3356

[3] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[4]

Ly C, 2003, CANCER RES, V63, P5716

[5] Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs [J].

Mohi, MG ;

Boulton, C ;

Gu, TL ;

Sternberg, DW ;

Neuberg, D ;

Griffin, JD ;

Gilliland, DG ;

Neel, BG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (09) :3130-3135

[6] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].

O'Brien, SG ;

Guilhot, F ;

Larson, RA ;

Gathmann, I ;

Baccarani, M ;

Cervantes, F ;

Cornelissen, JJ ;

Fischer, T ;

Hochhaus, A ;

Hughes, T ;

Lechner, K ;

Nielsen, JL ;

Rousselot, P ;

Reiffers, J ;

Saglio, G ;

Shepherd, J ;

Simonsson, B ;

Gratwohl, A ;

Goldman, JM ;

Kantarjian, H ;

Taylor, K ;

Verhoef, G ;

Bolton, AE ;

Capdeville, R ;

Druker, BJ ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shustik, C ;

Lipton, J ;

Forrest, D ;

Walker, I ;

Roy, DC ;

Rubinger, M ;

Bence-Bruckler, I ;

Kovacs, M ;

Turner, AR ;

Birgens, H ;

Bjerrum, O ;

Facon, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) :994-1004

[7] BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571:: a prospective study [J].

von Bubnoff, N ;

Schneller, F ;

Peschel, C ;

Duyster, J .

LANCET, 2002, 359 (9305) :487-491

[8] A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor [J].

von Bubnoff, N ;

Veach, DR ;

van der Kuip, H ;

Aulitzky, WE ;

Sänger, J ;

Seipel, P ;

Bornmann, WG ;

Peschel, C ;

Clarkson, B ;

Duyster, J .

BLOOD, 2005, 105 (04) :1652-1659

← 1 →